FR24C1053I2 - Utilisation du delgocitinib pour le traitement de l'eczéma des mains chronique - Google Patents

Utilisation du delgocitinib pour le traitement de l'eczéma des mains chronique

Info

Publication number: FR24C1053I2
Authority: FR; France
Prior art keywords: delgocitinib; treatment; hand eczema; chronic hand; chronic
Prior art date: 2016-01-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR24C1053C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Leo Pharma AS

Original Assignee

Leo Pharma AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-01-21

Filing date

2024-12-15

Publication date

2025-12-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55236207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR24C1053(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2024-12-15 Application filed by Leo Pharma AS filed Critical Leo Pharma AS

2025-02-21 Publication of FR24C1053I1 publication Critical patent/FR24C1053I1/fr

2025-12-05 Application granted granted Critical

2025-12-05 Publication of FR24C1053I2 publication Critical patent/FR24C1053I2/fr

Status Active legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Plant Substances (AREA)
Storage Of Fruits Or Vegetables (AREA)

FR24C1053C 2016-01-21 2024-12-15 Utilisation du delgocitinib pour le traitement de l'eczéma des mains chronique Active FR24C1053I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP16152215		2016-01-21
PCT/EP2017/051133 WO2017125523A1 (fr)	2016-01-21	2017-01-20	Traitement de l'eczéma des mains

Publications (2)

Publication Number	Publication Date
FR24C1053I1 FR24C1053I1 (fr)	2025-02-21
FR24C1053I2 true FR24C1053I2 (fr)	2025-12-05

Family

ID=55236207

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR24C1053C Active FR24C1053I2 (fr)	2016-01-21	2024-12-15	Utilisation du delgocitinib pour le traitement de l'eczéma des mains chronique

Country Status (31)

Country	Link
US (2)	US20200397787A1 (fr)
EP (2)	EP3405197B1 (fr)
JP (1)	JP6929860B2 (fr)
KR (2)	KR20180102662A (fr)
CN (3)	CN117159553A (fr)
AU (3)	AU2017209932A1 (fr)
BR (1)	BR112018014769A2 (fr)
CA (1)	CA3010547A1 (fr)
CY (2)	CY1126388T1 (fr)
DK (1)	DK3405197T3 (fr)
ES (1)	ES2963784T3 (fr)
FI (2)	FI3405197T3 (fr)
FR (1)	FR24C1053I2 (fr)
HR (1)	HRP20231448T1 (fr)
HU (2)	HUE064192T2 (fr)
IL (4)	IL297379A (fr)
LT (2)	LT3405197T (fr)
MX (2)	MX394358B (fr)
NL (1)	NL301306I2 (fr)
NO (1)	NO2024058I1 (fr)
PL (1)	PL3405197T3 (fr)
PT (1)	PT3405197T (fr)
RS (1)	RS64798B1 (fr)
RU (1)	RU2018130097A (fr)
SG (2)	SG10202006830WA (fr)
SI (1)	SI3405197T1 (fr)
SM (1)	SMT202300415T1 (fr)
TW (2)	TWI841027B (fr)
UA (1)	UA123780C2 (fr)
WO (1)	WO2017125523A1 (fr)
ZA (1)	ZA201804098B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112021022031A2 (pt) *	2019-05-15	2021-12-28	Leo Pharma As	Composto, composição farmacêutica, e, formulação farmacêutica para administração tópica
CN116847850A (zh) *	2021-02-02	2023-10-03	辉瑞公司	治疗慢性手部湿疹的给药方案
EP4376844A1 (fr) *	2021-07-30	2024-06-05	Eli Lilly and Company	Traitement de l'eczéma des mains à l'aide de baricitinib
AU2024238918A1 (en)	2023-03-17	2025-10-09	Leo Pharma A/S	A method for the treatment of chronic hand eczema in patients with moderate to severe chronic hand eczema

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI466885B (zh)	2009-07-31	2015-01-01	Japan Tobacco Inc	含氮螺環化合物及其醫藥用途
US20130302298A1 (en) *	2010-11-30	2013-11-14	Bio-K Plus International Inc.	Treatment and prevention of eczema
US20140343034A1 (en) *	2013-04-25	2014-11-20	Japan Tobacco Inc.	Skin barrier function improving agent

2017
- 2017-01-20 AU AU2017209932A patent/AU2017209932A1/en not_active Abandoned
- 2017-01-20 TW TW111141449A patent/TWI841027B/zh active
- 2017-01-20 EP EP17701828.0A patent/EP3405197B1/fr active Active
- 2017-01-20 UA UAA201808829A patent/UA123780C2/uk unknown
- 2017-01-20 CA CA3010547A patent/CA3010547A1/fr active Pending
- 2017-01-20 WO PCT/EP2017/051133 patent/WO2017125523A1/fr not_active Ceased
- 2017-01-20 ES ES17701828T patent/ES2963784T3/es active Active
- 2017-01-20 IL IL297379A patent/IL297379A/en unknown
- 2017-01-20 SG SG10202006830WA patent/SG10202006830WA/en unknown
- 2017-01-20 PT PT177018280T patent/PT3405197T/pt unknown
- 2017-01-20 RU RU2018130097A patent/RU2018130097A/ru unknown
- 2017-01-20 IL IL313543A patent/IL313543A/en unknown
- 2017-01-20 KR KR1020187024112A patent/KR20180102662A/ko not_active Ceased
- 2017-01-20 JP JP2018538167A patent/JP6929860B2/ja active Active
- 2017-01-20 CN CN202311350781.2A patent/CN117159553A/zh active Pending
- 2017-01-20 US US16/071,209 patent/US20200397787A1/en not_active Abandoned
- 2017-01-20 IL IL320757A patent/IL320757A/en unknown
- 2017-01-20 CN CN201780006075.2A patent/CN108472297A/zh active Pending
- 2017-01-20 SI SI201731440T patent/SI3405197T1/sl unknown
- 2017-01-20 DK DK17701828.0T patent/DK3405197T3/da active
- 2017-01-20 SM SM20230415T patent/SMT202300415T1/it unknown
- 2017-01-20 RS RS20231010A patent/RS64798B1/sr unknown
- 2017-01-20 FI FIEP17701828.0T patent/FI3405197T3/fi active
- 2017-01-20 LT LTEPPCT/EP2017/051133T patent/LT3405197T/lt unknown
- 2017-01-20 KR KR1020257019206A patent/KR20250088666A/ko active Pending
- 2017-01-20 MX MX2018008449A patent/MX394358B/es unknown
- 2017-01-20 TW TW106102111A patent/TWI783921B/zh active
- 2017-01-20 CN CN202311350784.6A patent/CN117159554A/zh active Pending
- 2017-01-20 SG SG11201805394QA patent/SG11201805394QA/en unknown
- 2017-01-20 EP EP23195420.7A patent/EP4257205A3/fr active Pending
- 2017-01-20 PL PL17701828.0T patent/PL3405197T3/pl unknown
- 2017-01-20 HU HUE17701828A patent/HUE064192T2/hu unknown
- 2017-01-20 BR BR112018014769-9A patent/BR112018014769A2/pt not_active Application Discontinuation
- 2017-01-20 HR HRP20231448TT patent/HRP20231448T1/hr unknown
2018
- 2018-06-18 IL IL260094A patent/IL260094A/en unknown
- 2018-06-19 ZA ZA2018/04098A patent/ZA201804098B/en unknown
- 2018-07-09 MX MX2022005915A patent/MX2022005915A/es unknown
2022
- 2022-07-08 US US17/811,347 patent/US20230138114A1/en active Pending
- 2022-10-13 AU AU2022252766A patent/AU2022252766B2/en active Active
2023
- 2023-11-10 CY CY20231100643T patent/CY1126388T1/el unknown
2024
- 2024-11-28 AU AU2024266962A patent/AU2024266962A1/en active Pending
- 2024-12-13 NO NO2024058C patent/NO2024058I1/no unknown
- 2024-12-13 NL NL301306C patent/NL301306I2/nl unknown
- 2024-12-15 FR FR24C1053C patent/FR24C1053I2/fr active Active
- 2024-12-17 CY CY2024037C patent/CY2024037I2/el unknown
- 2024-12-17 HU HUS2400045C patent/HUS2400045I1/hu unknown
- 2024-12-17 LT LTPA2024538C patent/LTPA2024538I1/lt unknown
- 2024-12-19 FI FIC20240048C patent/FIC20240048I1/fi unknown

Also Published As

Publication number	Publication date
HUS2400045I1 (hu)	2025-01-28
ZA201804098B (en)	2024-10-30
TW201736382A (zh)	2017-10-16
CN117159553A (zh)	2023-12-05
TWI783921B (zh)	2022-11-21
ES2963784T3 (es)	2024-04-02
KR20180102662A (ko)	2018-09-17
EP3405197B1 (fr)	2023-09-06
AU2022252766A1 (en)	2022-11-03
FIC20240048I1 (fi)	2024-12-19
TWI841027B (zh)	2024-05-01
AU2022252766B2 (en)	2024-08-29
CN108472297A (zh)	2018-08-31
AU2024266962A1 (en)	2024-12-19
EP4257205A3 (fr)	2023-12-20
CY2024037I1 (el)	2026-02-25
LTPA2024538I1 (fr)	2025-01-10
FR24C1053I1 (fr)	2025-02-21
NO2024058I1 (no)	2024-12-13
CY1126388T1 (el)	2026-02-25
LT3405197T (lt)	2023-11-27
US20200397787A1 (en)	2020-12-24
RU2018130097A (ru)	2020-02-21
HUE064192T2 (hu)	2024-02-28
SG11201805394QA (en)	2018-08-30
UA123780C2 (uk)	2021-06-02
PT3405197T (pt)	2023-12-06
JP2019502734A (ja)	2019-01-31
AU2017209932A1 (en)	2018-07-05
US20230138114A1 (en)	2023-05-04
IL320757A (en)	2025-07-01
DK3405197T3 (da)	2023-11-27
RS64798B1 (sr)	2023-11-30
IL313543A (en)	2024-08-01
IL297379A (en)	2022-12-01
MX2018008449A (es)	2018-08-09
SI3405197T1 (sl)	2024-03-29
PL3405197T3 (pl)	2024-02-12
SG10202006830WA (en)	2020-08-28
EP3405197A1 (fr)	2018-11-28
TW202332451A (zh)	2023-08-16
JP6929860B2 (ja)	2021-09-01
HRP20231448T1 (hr)	2024-03-01
SMT202300415T1 (it)	2024-01-10
FI3405197T3 (fi)	2023-11-23
BR112018014769A2 (pt)	2018-12-11
CA3010547A1 (fr)	2017-07-27
RU2018130097A3 (fr)	2020-05-25
MX2022005915A (es)	2022-06-27
MX394358B (es)	2025-03-24
NL301306I2 (nl)	2024-12-30
WO2017125523A1 (fr)	2017-07-27
NZ743582A (en)	2024-12-20
EP4257205A2 (fr)	2023-10-11
CY2024037I2 (el)	2026-02-25
IL260094A (en)	2018-07-31
CN117159554A (zh)	2023-12-05
KR20250088666A (ko)	2025-06-17

Publication	Publication Date	Title
FR25C1001I2 (fr)	2026-01-02	Compositions d'anticorps pour le traitement de tumeurs
FR25C1041I1 (fr)	2025-12-19	Elafibranor pour l'utilisation dans le traitement de la cholangite biliaire primitive
MA45481A (fr)	2018-04-18	Utilisation d'exosomes pour le traitement de maladies
MA49144A (fr)	2020-03-25	Polythérapies pour le traitement du cancer
MA45539A (fr)	2019-05-08	Dihydropyranopyrimidines pour le traitement d'infections virales
EP3504187A4 (fr)	2020-05-06	Utilisation de la pridopidine pour le traitement du déclin fonctionnel
MA47719A (fr)	2020-01-15	Esketamine pour le traitement de la dépression
MA50409A (fr)	2020-08-26	Polythérapies pour le traitement du cancer
MA48637A (fr)	2021-03-17	Polythérapies pour le traitement du cancer
EP3380200A4 (fr)	2019-07-17	Compositions pour le traitement des cheveux
FR24C1053I1 (fr)	2025-02-21	Utilisation du delgocitinib pour le traitement de l'eczéma des mains chronique
EP3503890A4 (fr)	2020-05-06	Utilisation de la pridopidine pour le traitement des dystonies
MA42999A (fr)	2018-08-22	Polythérapie pour le traitement de malignités
EP3541417A4 (fr)	2020-05-27	Immunothérapies d'association pour le traitement du cancer
EP3389645A4 (fr)	2019-12-18	Combinaisons pour le traitement du cancer
EP3380063A4 (fr)	2019-08-07	Compositions pour le traitement des cheveux
EP3359255A4 (fr)	2019-06-12	Polythérapies pour le traitement du cancer
EP3490561A4 (fr)	2020-04-08	Combinaisons pour le traitement du cancer
EP3541379A4 (fr)	2020-05-27	Compositions pour le traitement de l'hypertension
EP3344325A4 (fr)	2019-05-15	Administration locale de médicaments pour le traitement de l'asthme
MA45492A (fr)	2019-05-01	Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène
EP3512506A4 (fr)	2020-05-27	Utilisation de la pridopidine pour le traitement du syndrome de rett
EP3334432A4 (fr)	2019-03-13	Cerdulatinib pour le traitement du myélome
EP3630080A4 (fr)	2021-03-10	Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
EP3430400A4 (fr)	2019-10-30	Schémas posologiques pour le traitement d'infections fongiques